AstraZeneca vaccine and Guillain-Barré syndrome: There’s minimal cause for concern
The Therapeutic Goods Administration (TGA) yesterday revealed there have been six reports of Guillain-Barré syndrome in Australia following the AstraZeneca COVID vaccine.